Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD ...
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) yesterday announced that Japan's Ministry of Health, Labor and Welfare has approved Dupixent for children aged 6 to 11 years with ...
New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...
Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...
Investor's Business Daily on MSN
Sanofi edges higher as immunology powerhouse, Dupixent, wallops forecasts
Sanofi stock edged higher Thursday after its immunological powerhouse, Dupixent, handily beat Wall Street's fourth-quarter expectations.
Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results